Amarantus BioScience, Inc. (AMBS)
-OTC Markets 0.04 May 20, 3:43PM EDT|Pre-Market
:
NaN
| Prev Close: | 0.04 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | 3.214 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 0.04 - 0.10 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 3,790,220 |
|---|
| Market Cap: | 16.13M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.04 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Amarantus to Present at the 2nd Annual Marcum MicroCap Conference on May 30PR Newswire(Mon, May 20)
- Amarantus BioScience President and CEO Publishes New Blog Entitled ''Continued Progress with our Business Plan in Central Nervous System Disorders''Accesswire(Thu, May 16)
- AMARANTUS BIOSCIENCE HOLDINGS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 15)
- AMARANTUS BIOSCIENCE HOLDINGS, INC. Files SEC form 8-K, Other EventsEDGAR Online(Fri, May 10)
- Amarantus Provides Update on #C4CT Concussion Awareness Summit on June 21 in MinneapolisBusiness Wire(Mon, May 6)
- AMARANTUS BIOSCIENCE HOLDINGS, INC. FinancialsEDGAR Online Financials(Thu, May 2)
- Amarantus Posts Review of MANF Literature to Web SiteBusiness Wire(Wed, May 1)
- OTCBB Journal Where Savvy Traders Get the Hottest Due Diligence Issues New Micro-Cap Stock ReportMarketwired(Mon, Apr 29)
- AMARANTUS BIOSCIENCE HOLDINGS, INC. Files SEC form 10-K/A, Annual ReportEDGAR Online(Fri, Apr 26)
- Amarantus Posts LymPro Test® Alzheimer’s Diagnostic White Paper to Web SiteBusiness Wire(Thu, Apr 25)
- Amarantus Appoints Russell Miller as Director of Investor RelationsBusiness Wire(Tue, Apr 23)
- AMARANTUS BIOSCIENCE HOLDINGS, INC. Files SEC form 8-K, Other EventsEDGAR Online(Fri, Apr 19)
- AMARANTUS BIOSCIENCE HOLDINGS, INC. FinancialsEDGAR Online Financials(Wed, Apr 17)
- AMARANTUS BIOSCIENCE HOLDINGS, INC. FinancialsEDGAR Online Financials(Wed, Apr 17)
- Amarantus LymPro Could Be A Game-Changer For Alzheimer's Diagnosisat Seeking Alpha(Wed, Apr 17)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Amarantus BioScience Holdings, Inc., a development-stage biotechnology company, focuses on the discovery and development of drug candidates and diagnostic blood tests to diagnose and treat human diseases in the United States.
View More 
0.12%